| Symbol | RNTX |
|---|---|
| Name | REIN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 285 SUMMER STREET,UNIT 101, BOSTON, Massachusetts, 02210, United States |
| Telephone | +1 617 995-0900 |
| Fax | — |
| — | |
| Website | https://www.reintx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001420565 |
| Description | Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Companys lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis). Additional info from NASDAQ: |
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Read moreNew Form SCHEDULE 13G - Rein Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097425 <b>Size:</b> 15 KB
Read moreRein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreNew Form SCHEDULE 13G/A - Rein Therapeutics, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0000935836-26-000391 <b>Size:</b> 6 KB
Read moreRein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
Read moreNew Form ARS - Rein Therapeutics, Inc. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0001193125-26-260814 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Rein Therapeutics, Inc. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0001193125-26-260812 <b>Size:</b> 2 MB
Read moreNew Form DEF 14A - Rein Therapeutics, Inc. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0001193125-26-260809 <b>Size:</b> 5 MB
Read moreVON RICKENBACH JOSEF H 🟢 acquired 47.1K shares of Rein Therapeutics, Inc. (RNTX) at $1.07 Transaction Date: May 21, 2026 | Filing ID: 245832
Read more